Cellbxhealth PLC Announces Expert Consensus on CTCs; Update on Funding
CelLBxHealth (OTCQX:ANPCF) welcomed an international expert consensus published 4 November 2025 that affirms the clinical relevance of circulating tumor cells (CTCs) and highlights the Parsortix® platform.
The consensus of 32 experts found that CTCs provide information distinct from ctDNA, 90% of respondents expect CTC testing to become routine within five years, and 40% identified Parsortix as the most promising next‑generation technology. The company also updated funding: cash runway into early 2026 and an intention to raise about £6m, with a fundraise announcement expected by early December 2025.
CelLBxHealth (OTCQX:ANPCF) ha accolto un consenso esperto internazionale pubblicato il 4 novembre 2025 che afferma la rilevanza clinica delle cellule tumorali circolanti (CTC) e mette in evidenza la piattaforma Parsortix®.
Il consenso di 32 esperti ha rilevato che le CTC forniscono informazioni distinte dal ctDNA, 90% dei rispondenti si aspettano che i test CTC diventino di routine entro cinque anni, e 40% hanno identificato Parsortix come la tecnologia di prossima generazione più promettente. L'azienda ha inoltre aggiornato il funding: una runway di cassa fino a inizio del 2026 e l'intenzione di raccogliere circa £6m, con un annuncio di aumento di capitale previsto entro inizio dicembre 2025.
CelLBxHealth (OTCQX:ANPCF) dio la bienvenida a un consenso experto internacional publicado el 4 de noviembre de 2025 que afirma la relevancia clínica de las células tumorales circulantes (CTCs) y destaca la plataforma Parsortix®. El consenso de 32 expertos encontró que las CTCs proporcionan información distinta del ctDNA, 90% de los encuestados espera que las pruebas de CTC se vuelvan rutinarias dentro de cinco años, y 40% identificaron Parsortix como la tecnología de próxima generación más prometedora. La empresa también actualizó su financiación: una carrera de efectivo hasta principios de 2026 y la intención de recaudar alrededor de £6m, con un anuncio de financiación previsto para principios de diciembre de 2025.
CelLBxHealth (OTCQX:ANPCF)는 2025년 11월 4일 발표된 국제 전문가 합의가 순환 종양세포(CTC)의 임상적 관련성을 확인하고 Parsortix® 플랫폼을 강조한다고 환영했다.
32명의 전문가 합의는 CTC가 ctDNA와 구별되는 정보를 제공하며, 90%의 응답자가 5년 이내에 CTC 검사의 일상화가 이뤄질 것으로 예상하고, 40%가 Parsortix를 차세대 기술 중 가장 유망한 것으로 확인했다. 또한 회사는 자금 조달도 업데이트했다: 현금 운용 기간이 초기 2026년까지이며, 약 £6m를 모금할 의향이 있으며, 자금 조달 발표를 2025년 12월 초에 예상한다.
CelLBxHealth (OTCQX:ANPCF) a accueilli un consensus d'experts international publié le 4 novembre 2025 qui affirme la pertinence clinique des cellules tumorales circulantes (CTC) et met en lumière la plateforme Parsortix®. Le consensus de 32 experts a constaté que les CTC fournissent des informations distinctes du ctDNA, 90% des répondants s'attendent à ce que les tests CTC deviennent routiniers dans les cinq ans, et 40% ont identifié Parsortix comme la technologie de prochaine génération la plus prometteuse. L'entreprise a également mis à jour son financement : une trésorerie jusqu'au début de 2026 et l'intention de lever environ £6m, avec une annonce de levée de fonds attendue pour le début décembre 2025.
CelLBxHealth (OTCQX:ANPCF) begrüßte einen internationalen Expertenkonsens, der am 4. November 2025 veröffentlicht wurde und die klinische Relevanz zirkulierender Tumorzellen (CTCs) bestätigt und die Parsortix®-Plattform hervorhebt.
Der Konsens von 32 Experten fand heraus, dass CTCs Informationen liefern, die sich von ctDNA unterscheiden, 90% der Befragten erwarten, dass CTC-Tests innerhalb von fünf Jahren zur Routine werden, und 40% identifizierten Parsortix als die vielversprechendste Next-Generation-Technologie. Das Unternehmen aktualisierte auch die Finanzierung: eine Cash-Runway bis in Anfang 2026 und die Absicht, ca. £6m zu beschaffen, mit einer Ankündigung der Finanzierung voraussichtlich bis Anfang Dezember 2025.
CelLBxHealth (OTCQX:ANPCF) رحّبت بإجماع خبراء دولي نُشر في 4 نوفمبر 2025 يؤكد الصلة السريرية للخلايا الورمية الدائرة (CTCs) ويبرز منصة Parsortix®. وجد الإجماع المكوّن من 32 خبيراً أن CTCs تُقدم معلومات مميزة عن ctDNA، وأن 90% من المستجيبين يتوقعون أن تصبح اختبارات CTC روتينية خلال خمس سنوات، وأن 40% حددوا Parsortix كتقنية الجيل التالي الأكثر وعداً. كما قامت الشركة بتحديث التمويل: مدى زمني نقدي حتى أوائل 2026 ونية لجمع نحو £6m، مع إعلان عن جمع التمويل المتوقع في أوائل ديسمبر 2025.
- Independent consensus: 32 experts endorse CTC clinical relevance
- 90% of panel expect routine CTC use within five years
- 40% of panel identified Parsortix as leading next‑gen CTC tech
- Cash runway extends only to early 2026
- Company seeks to raise approximately £6m, implying potential dilution
Independent Expert Consensus Confirms Clinical Relevance of CTCs and Identifies Parsortix Platform as Leading Next-Generation Technology
Expert consensus predicts integration of CTC testing into routine clinical practice within 5 years
CTCs provide distinct and impactful information that is not captured by circulating tumour DNA (ctDNA)
40% of the expert panel identified the Parsortix® platform as the most promising next generation technology for clinical applications
PLYMOUTH MEETING, PA AND GUILFORD, SURREY / ACCESS Newswire / November 4, 2025 / CELLBXHEALTH plc (AIM:CLBX)(OTCQX:ANPCY), a global leader in circulating tumour cell (CTC) intelligence, welcomes the publication of a major international expert consensus confirming the growing clinical relevance of CTC analysis in cancer management. The study, titled "International expert consensus on the clinical integration of circulating tumor cells in solid tumors", and published in the high-impact factor journal the European Journal of Cancer, highlights the Parsortix® platform as a leading future technology for clinical application.
The paper publishes the consensus of 32 global oncologists and research leaders who agree that CTCs provide unique biological insights not captured by circulating tumour DNA (ctDNA), and that CTCs are poised to transform cancer care through their use in prognosis, treatment monitoring and characterisation to inform precision medicine.
The Company believes this publication strengthens the foundation for clinical adoption of CTC-based technologies, aligning with its mission to advance precision oncology.
Update on Funding
Further to the interim results of 9 October 2025, the Company currently has a cash runway into early 2026. CelLBxHealth has recently commenced discussions with a number of shareholders and is seeking to raise approximately
The Company expects to announce the fundraise by early December and will make further updates as appropriate.
Peter Collins, Chief Executive Officer of CelLBxHealth, said: "This independent expert consensus further demonstrates the important role that CTCs stand to play in cancer treatment into the future, and identifies the Parsortix® platform as a go-to platform in the space. In this context, CelLBxHealth is uniquely positioned as the next generation standard to enable clinicians and researchers to harness the full diagnostic and therapeutic potential of CTCs.
We look forward to engaging with shareholders and potential investors as we reset the Company to deliver sustainable growth."
The peer reviewed manuscript, is available online: Nicolò, E. et al. (2025). International expert consensus on the clinical integration of circulating tumor cells in solid tumors. European Journal of Cancer, 231, 116050. https://doi.org/10.1016/j.ejca.2025.116050
For more information, visit www.CelLBxHealth.com
For further information:
CelLBxHealth plc Peter Collins, Chief Executive Officer | +44 (0) 1483 343434 |
Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper (Corporate Finance) | +44 (0) 20 7220 0500 |
FTI Consulting Simon Conway, Ciara Martin, Sam Purewal | +44 (0) 203 727 1000 |
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014).Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
Notes for editors
About CelLBxHealth plc
CelLBxHealth plc is a global precision CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be seamlessly integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.
Commercial activities centre on (1) Product Sales: Accelerating Parsortix platform adoption and consumable sales through CROs* and clinical lab partnerships. (2) Lab Developed Tests (LDTs): Strategic partnerships combined with a focused in-house development programme (3) Laboratory services: Clinical trial support and assay development.
The product portfolio comprises the Parsortix® platform with associated consumables and assays. Laboratory services are delivered from CelLBxHealth's GCLP certified UK laboratory, providing bespoke clinical-trial support and assay development.
For more information, visit www.angleplc.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Cellbxhealth PLC
View the original press release on ACCESS Newswire
FAQ
What did CelLBxHealth announce on 4 November 2025 regarding CTCs and ANPCF?
How soon do experts expect CTC testing to be routine for cancer care (ANPCF news)?
What role did the Parsortix platform receive in the CelLBxHealth announcement (ANPCF)?
What is CelLBxHealth's current cash runway and fundraising target mentioned in the November 4, 2025 update?
When does CelLBxHealth expect to announce the planned fundraise for ANPCF investors?
